Yesterday, the CEO of Ligand Pharma (LGND), John L. Higgins, bought shares of LGND for $176.6K.
This recent transaction increases John L. Higgins’ holding in the company by 1.28% to a total of $13.43 million.
See today’s analyst top recommended stocks >>
LGND’s market cap is $1.79B and the company has a P/E ratio of 2.92. Currently, Ligand Pharma has an average volume of 987.6K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $160.75, reflecting a 75.7% upside. Three different firms, including Argus Research and Stephens, currently also have a Buy rating on the stock.
The insider sentiment on Ligand Pharma has been positive according to 54 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
John L. Higgins’ trades have generated a 15.6% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
